Crossvault Capital Management’s GSK GSK Stock Holding History

Crossvault Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$400K	Sell	7,353 -1,000	-12%	-$55.2K	0.16%	58
2022 Q1	$455K	Hold	8,353	–	–	0.15%	55
2021 Q4	$460K	Buy	8,353 +260	+3%	+$13.5K	0.14%	56
2021 Q3	$387K	Hold	8,093	–	–	0.12%	59
2021 Q2	$406K	Sell	8,093 -1,040	-11%	-$50K	0.12%	58
2021 Q1	$407K	Sell	9,133 -280	-3%	-$12.7K	0.15%	60
2020 Q4	$433K	Hold	9,413	–	–	0.16%	53
2020 Q3	$443K	Hold	9,413	–	–	0.19%	55
2020 Q2	$480K	Hold	9,413	–	–	0.22%	50
2020 Q1	$446K	Hold	9,413	–	–	0.25%	52
2019 Q4	$553K	Sell	9,413 -50	-0.5%	-$2.78K	0.24%	56
2019 Q3	$505K	Buy	9,463 +490	+5%	+$25.2K	0.24%	55
2019 Q2	$449K	Sell	8,973 -140	-2%	-$7.03K	0.22%	57
2019 Q1	$476K	Hold	9,113	–	–	0.25%	53
2018 Q4	$435K	Buy	9,113 +160	+2%	+$7.88K	0.25%	55
2018 Q3	$450K	Buy	8,953 +3,940	+79%	+$200K	0.23%	49
2018 Q2	$253K	Buy	+5,013	New	+$252K	0.13%	56

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Crossvault Capital Management's GSK Position: Q2 2022 in Review

Crossvault Capital Management reduced its GSK (GSK) stake by 12% in Q2 2022, selling an estimated $55.2K and leaving 7,353 shares worth $400K. The position accounts for 0.16% of the portfolio, ranked #58.

Crossvault Capital Management first reported a position in GSK in Q2 2018 and has held it in 17 quarters since. The position peaked at $553K in Q4 2019. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

Crossvault Capital Management held 7,353 shares of GSK worth $400K as of Q2 2022.
Crossvault Capital Management sold 1,000 GSK shares in Q2 2022, an estimated $55.2K.
GSK made up 0.16% of Crossvault Capital Management's portfolio in Q2 2022, its #58 holding.
Crossvault Capital Management first reported a position in GSK in Q2 2018 and has held it in 17 quarters since.
Crossvault Capital Management's GSK position peaked at $553K in Q4 2019.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Crossvault Capital Management's 13F filing for Q2 2022, filed 8 Aug 2022.